ACME UNITED Q1 2026: Revenue Rises on My Medic, But EPS Dips as Tariffs and Costs Nibble at Margins

Earnings snapshot: the numbers tell the story

ACME United Corporation (NYSE American: ACU) reported first-quarter 2026 net sales of $52.3 million, up from $46.0 million in the same quarter a year earlier — a solid 14% year-over-year rise. The gain was helped in part by the recently acquired My Medic business, which directed more revenue through direct-to-consumer channels but contributed only modestly to earnings in Q1.

Net income came in at $1.0 million, or $0.24 per diluted share, versus $1.7 million, or $0.41 per diluted share, in Q1 2025. The press release notes that the delta in earnings and EPS reflects higher costs of sales and operating expenses, plus tariff-related costs and investments in enhanced quality assurance at the Med-Nap facility, alongside rising employee healthcare costs. Tariff expenses were taken as the company sold inventory that had been priced under higher tariff rates imposed in 2025.

In other words, the headline revenue growth did not translate into proportionate profit growth in the quarter. The company also highlighted the contribution of the My Medic business to sales, while indicating that its profitability is expected to materialize more meaningfully in the fourth quarter, given the business’s direct-to-consumer seasonal model.

On the earnings front, the quarter produced an EPS of $0.24 vs. $0.41 in the prior year period — a drop described by the company as a 40% decline in net income and a 41% decline in diluted earnings per share. There is no disclosed EPS consensus in the filing, so readers may measure this against internal expectations or external estimates, but the document itself notes the concrete results rather than a market-wide benchmark. This nuance feeds into how one might classify the result in terms of an earnings surprise or deviation from expectations (if any) implied by prior guidance or peer expectations.

What the results imply for profitability and strategy

The top line is moving in the right direction, powered in part by the My Medic acquisition and stronger demand for recreational and emergency-response products in the period. But the margin picture is cloudier. Tariffs, higher cost of sales, and rising healthcare costs squeezed margins in the quarter. The company notes that tariff-related costs were recognized as inventory with higher tariff rates remained on the balance sheet for sale early in 2026, a timing dynamic that can distort quarterly profitability even when the underlying business is expanding.

ACME United also points to strategic investments—most notably a move into a new Spill Magic facility in Tennessee—as a driver of longer-run efficiency. The commentary suggests that, once the capacity is fully utilized, the company could realize a more favorable cost structure. In this sense, the quarter reads like a transition: a growth engine (My Medic) fueling revenue, paired with cost and integration hurdles that can dampen near-term earnings.

Acquisition impact and product mix: a closer look

The My Medic acquisition broadens ACU’s product portfolio in tactical, trauma, and emergency response segments and accelerates direct-to-consumer channel expansion. Management characterizes My Medic as a seasonal business whose profitability is likely to peak in the fourth quarter. That seasonal tail, plus integration costs, will likely weigh on quarterly earnings if investors expect immediate earnings leverage from the acquisition.

From a portfolio perspective, the mix tilt toward consumer-facing channels could improve brand reach and cross-selling opportunities, even if the near-term margins are challenged by product mix and tariff exposure. The question for investors becomes: will the incremental top-line growth translate into sustainable earnings expansion as the integration matures and as cost controls take hold?

Outlook and sector implications

The company did not provide a formal full-year revenue forecast or EPS guidance in this release. The emphasis appears to be on the timing of profitability improvements tied to the My Medic rollout and the Tennessee facility’s cost efficiencies, rather than on a precise 2026 earnings trajectory. For investors, the absence of a crisp revenue forecast or EPS target means more reliance on cadence signals—seasonality, cost normalization, and the pace of My Medic’s profitability writ large.

Within the broader sector, ACU’s experience underscores a familiar dynamic: acquisitions can rapidly augment revenue streams and market reach, but the integration path often entails higher near-term operating costs and mix-related margin pressure. Tariff headwinds and healthcare-related cost pressures add another layer of complexity to projections across consumer healthcare and safety products peers. If ACME United’s cost controls and operational enhancements begin to bear fruit in the back half of 2026, the stock could re-rate on improved earnings visibility, particularly if the My Medic profit contribution scales as expected.

Takeaways for investors and peers

• Ticker and earnings metrics: ACU remains exposed to cost pressures that can erode EPS even as revenue grows; the reported EPS of $0.24 in Q1 contrasts with prior-year earnings of $0.41, signaling a near-term margin hurdle.
• Earnings surprise and EPS consensus: While there is no EPS consensus disclosed in the filing, the quarterly result shows a divergence from prior profitability levels, which could be interpreted variably depending on expectations for the My Medic integration and tariff normalization.
• Revenue forecast considerations: The absence of a formal full-year revenue forecast means investors will watch quarterly progress against the plan for improved profitability from the Tennessee facility and the My Medic brand.
• Strategic trajectory: The push into direct-to-consumer through My Medic and the operational efficiency drive from new facilities could position ACU for stronger profitability once the integration and seasonality effects settle.

The bottom line

ACME United’s Q1 2026 narrative is familiar in the post-acquisition playbook: revenue strength from an expanded product suite, tempered by cost headwinds and transitional margins. The company’s emphasis on profitability timing—anticipating stronger gains in Q4 as My Medic matures—introduces a potential hinge point for the stock. For investors tracking ACU, the near-term focus will be on whether tariff-driven cost pressures can be absorbed and whether the new Tennessee facility yields sustainable cost savings. The earnings-per-share picture will follow the same arc—the top line looks healthier; the bottom line still needs time to catch up.

In short, ACU’s first quarter is less a victory lap than a strategic repositioning: more revenue from growth platforms, and a plan to convert that revenue into meaningful earnings as the year progresses. If you’re watching EPS, keep an eye on the trajectory toward a stabilized or expanding EPS consensus over the next few quarters, as the My Medic ramp and tariff normalization play out across the company’s cost structure and product mix.